Interestingly, another previous study demonstrated that the number of Meflin+ rCAFs positively correlated with the response to immune checkpoint blockade (ICB) therapy in patients with non-small cell lung cancer (NSCLC) [28]. This evidence concerns the gene ISLR and non-small cell lung carcinoma.